A Phase II trial evaluating nivolumab (PD-1 inhibitor) combined with azacitidine in relapsed/refractory AML reported a 33% overall response rate and a median OS of 6.3 months but with limited long-term benefit (58). Here, PDCD1 is linked to acute myeloid leukemia.